Pfizer revealed on Wednesday that it had finally dosed its first patient participating in the Phase 2/3 study examining the efficacy of PF- 07321332, an orally administered protease inhibitor antiviral designed to combat COVID-19. The randomized, double-blind trial will enroll approximately 1,140 participants, who will receive PF07321332/ritonavir, or a placebo, orally every 12 hours for five days.
Pfizer CEO Albert Bourla weighed in via tweet:
Click for Full Text!
Poster Comment:
WTAF?